---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-103126"
form_type: "8-K"
ticker: "CADL"
cik: "0001841387"
company_name: "Candel Therapeutics, Inc."
filed_at: "2026-03-12T23:59:59+00:00"
generated_at: "2026-05-15T13:49:55.383707+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Candel reports Q4 2025 net loss of $29.5M; cash $119.7M; plans BLA for aglatimagene in Q4 2026

## Summary
- Net loss Q4 2025: $29.5M vs $14.1M Q4 2024; full year net loss $38.2M vs $55.2M (2024).
- Cash $119.7M at Dec 31, 2025; plus $93.5M net from Feb 2026 offering; runway into Q1 2028.
- Entered $130M term loan with Trinity Capital; $50M drawn; $100M royalty deal with RTW contingent on FDA approval.
- Plan to initiate pivotal phase 3 trial of aglatimagene in NSCLC in Q2 2026; BLA submission for prostate cancer in Q4 2026.
- FDA cleared IND for linoserpaturev in recurrent high-grade glioma; mature OS data expected Q4 2026.

## SEC filing metadata
- accession: 0001193125-26-103126
- form_type: 8-K
- ticker: CADL
- cik: 0001841387
- company_name: Candel Therapeutics, Inc.
- filed_at: 2026-03-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1841387/000119312526103126/0001193125-26-103126-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1841387/000119312526103126/cadl-20260312.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-103126
- JSON: https://secwatch.observer/filing/0001193125-26-103126.json
- Plain text: https://secwatch.observer/filing/0001193125-26-103126.txt

## Key facts
- Earnings Releases
  Candel Therapeutics, Inc. reported financial results for the quarter and year ended December 31, 2025.
  - Period: the quarter and year ended December 31, 2025
  - Result: reported results
  source text: On March 12, 2026, Candel Therapeutics, Inc. announced its financial results for the quarter and year ended December 31, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1841387/000119312526103126/0001193125-26-103126-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.